Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | AGPAT2 | O15120 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785145 | 0.86 | EGFR (0.54) | SMN1; SMN2ALDH1A1KMT2AMEN1AGPAT2 | |
| SCHEMBL116096 | 0.85 | EPHX1 (0.66) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL4894719 | 0.85 | EPHX1 (0.66) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL12900900 | 0.84 | HPGD (0.70) | SMN1; SMN2ALDH1A1KMT2AMEN1AGPAT2 | |
| SCHEMBL13329852 | 0.84 | MEN1 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL3789950 | 0.83 | CA12 (0.48) | ALDH1A1KMT2AMEN1EPHX1EPHX2 | |
| SCHEMBL3788235 | 0.83 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1KMT2AMEN1AGPAT2 | |
| SCHEMBL11657782 | 0.83 | HPGD (0.69) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL3786769 | 0.83 | POLB (0.58) | SMN1; SMN2ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL2091861 | 0.82 | NPC1 (0.55) | SMN1; SMN2AGPAT2HPGDKDM4EEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | SMN1; SMN2 4524/4885ALDH1A1 4339/4885KMT2A 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.